Unith Ltd

UNT

Unith Ltd. operates as a holding company, which engages in developing information services for users of mobile phones and tablet devices. The company is headquartered in Melbourne, Victoria. The company unifies the research and development of facial movement, deep learning, audio, machine learning and conversational design to generate the first customizable, interactive avatar of its kind. Through its platform, businesses can create their own digital humans to immerse, assist, and educate customers in real time and in multiple languages. The Company’s segments include Mobile Content - Subscription, Digital Humans and Other Segments. Mobile Content - Subscription segment provides mobile subscription-based content offering of products, such as mobile security, games and video portals via a mobile payments network and the underlying artificial intelligence (AI)-driven technology platform. The Digital Humans business-to-business (B2B) software-as-a-service (SaaS) division creates and licenses engaging, user-centric conversations in real time with AI-powered digital humans.

VanEck MSCI International Sustainable Equity ETF

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

Global X Battery Tech & Lithium ETF

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 493.8m in AUM and 35 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Leederville, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.